MeiraGTx Holdings plc (MGTX): Total Assets
$244.43M
As of 2025-12-31
$396.45M
As of 2026-06-30
-8.4%
3-year compound annual growth
-7.6%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $244.43M | -9.4% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $269.75M | -17.4% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $326.74M | +2.7% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $318.24M | -0.6% | 2024-03-15, Balance as of period end |
| 2021-12-31 | $320.16M | -12.0% | 2023-03-14, Balance as of period end |
| 2020-12-31 | $363.70M | +12.3% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $323.89M | +234.3% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $96.89M | +274.8% | 2020-03-11, Balance as of period end |
| 2017-12-31 | $25.85M | n/a | 2019-03-26, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $244.43M | -9.4% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $566.71M | +1.1% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $589.07M | -24.7% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $1.47B | +1.8% |
| Compugen Ltd (CGEN) | 2025-12-31 | $156.57M | +36.2% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $143.01M | +16.6% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $1.00B | -28.3% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $173.83M | -55.1% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $223.70M | -36.7% |
Compare MGTX, FDMT, AUTL, RXRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗